Soleno Therapeutics (SLNO) Income towards Parent Company: 2013-2017
Historic Income towards Parent Company for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to -$544,000.
- Soleno Therapeutics' Income towards Parent Company rose 54.35% to -$544,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$3.6 million, marking a year-over-year increase of 52.99%. This contributed to the annual value of -$175.8 million for FY2024, which is 353.15% down from last year.
- Per Soleno Therapeutics' latest filing, its Income towards Parent Company stood at -$544,000 for Q4 2017, which was up 57.96% from -$1.3 million recorded in Q3 2017.
- Over the past 5 years, Soleno Therapeutics' Income towards Parent Company peaked at -$544,000 during Q4 2017, and registered a low of -$4.3 million during Q1 2016.
- For the 3-year period, Soleno Therapeutics' Income towards Parent Company averaged around -$1.9 million, with its median value being -$1.3 million (2016).
- As far as peak fluctuations go, Soleno Therapeutics' Income towards Parent Company tumbled by 379.25% in 2014, and later spiked by 80.25% in 2017.
- Quarterly analysis of 5 years shows Soleno Therapeutics' Income towards Parent Company stood at -$869,278 in 2013, then crashed by 379.25% to -$4.2 million in 2014, then grew by 15.85% to -$3.5 million in 2015, then soared by 66.01% to -$1.2 million in 2016, then soared by 54.35% to -$544,000 in 2017.
- Its last three reported values are -$544,000 in Q4 2017, -$1.3 million for Q3 2017, and -$913,000 during Q2 2017.